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Longitudinal relationship between solute transport and ultra-
filtration capacity in peritoneal dialysis patients.
Background. Time on treatment is associated with a greater
risk of impaired ultrafiltration (UF) in peritoneal dialysis (PD)
patients. In addition to increasing solute transport, a potentially
treatable cause of impaired ultrafiltration, cross-sectional stud-
ies suggest that there is also reduced osmotic conductance of
the membrane. If this were the case then it would be expected
that the UF capacity for a given rate of solute transport would
change with time. The purpose of this analysis was to establish
how solute transport and UF capacity change relative to one
another with time on therapy.
Methods. Membrane function, using a standard peritoneal
equilibration test, was measured at least annually in a well-
characterized, single-center observational cohort of PD patients
between 1990 and 2003. Demography included age, gender,
original cause of renal failure, body surface area (BSA), val-
idated comorbidity score, residual urine volume and urea clear-
ances, peritoneal urea clearances, and plasma albumin.
Results. Data from 574 new PD patients were available
for analysis. Independent demographic factors associated with
higher solute transport at baseline were male gender and higher
residual urine volume. Throughout time on therapy there was a
negative relationship between solute transport and UF capac-
ity and a significant increase and decrease in these parameters,
respectively. During the first 12 months of treatment, the in-
crease in solute transport was not associated with the expected
fall in UF capacity, a phenomenon that was not explained by
informative censoring, but was associated with an increased, al-
beit weak, correlation with BSA. In contrast, later in treatment
there was a disproportionate fall in UF capacity, more acceler-
ated in patients developing UF failure. Early exposure to higher
intraperitoneal glucose concentrations, in the context of more
comorbidity and relative lack of residual renal function, was as-
sociated with more rapid deterioration in membrane function.
Conclusion. Despite a causal link between solute transport
and UF capacity of the membrane, due to the effect of the for-
mer on the osmotic gradient, there is evidence of their longitudi-
nal dissociation. This implies a change in the structure-function
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relationship with time on treatment that can, to some extent,
be predicted from clinical factors present within the first year
of treatment. Dialysis-induced membrane injury must involve
at least two processes, for example, increased vascular surface
area contact with dialysate combined with changes in hydraulic
conductance due to scarring of the vessels and interstitium.
Impaired peritoneal removal of salt and water, es-
pecially in functionally anuric patients, is an important
cause of reduced patient and technique survival in peri-
toneal dialysis (PD) patients [1–3]. Until recently this
problem was most clearly identified in continuous am-
bulatory peritoneal dialysis (CAPD) patients with high
peritoneal solute transport characteristics [4–6]. High
transport results in impaired ultrafiltration (UF) due to
the more rapid absorption of glucose and earlier loss
of the osmotic driving force for fluid transport across
the peritoneal membrane. This problem can be largely
avoided, however, by the use of automated peritoneal
dialysis (APD) to enable shortening of dwell length to
prevent fluid reabsorption [3, 7], and by using polyglu-
cose solutions during the long dwell period, where they
will result in sustained ultrafiltration and improvement
in fluid status [8, 9]. Despite these clinical tools, however,
there is still evidence that adequate fluid removal remains
a clinical problem [3].
Cross-sectional studies have consistently shown that
there appears to be more than one mechanism underly-
ing ultrafiltration failure [10, 11]. While high small so-
lute transport remains a common cause, these studies
also suggest that the achieved ultrafiltration for a given
osmotic gradient appears to be worse, even when other
mechanisms, such as fluid reabsorption, are taken into ac-
count [12]. This reduction in osmotic conductance of the
peritoneum will result in a relative fall in the ultrafiltra-
tion capacity for a given level of solute transport, both of
which can be measured easily in PD patients by employ-
ing the Peritoneal Equilibration Test (PET), as described
by Twardowski [13]. The purpose of the present study was
to show how these two measures of membrane function
evolve longitudinally with time on treatment in a large,
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single-center cohort with significant numbers of patients
completing up to 7 years of continuous therapy. Specifi-
cally, the relationship between these 2 parameters was an-
alyzed to establish if it changes with time on treatment,
as would be predicted from the cross-sectional studies,
and, if possible, to identify risk factors for the evolution
of membrane failure.
METHODS
Study design and patients studied
This was a prospective, single-center cohort study of
consecutive new patients commencing peritoneal dialy-
sis from January 1990 until the data were censored in
November 2003. Data were collected within the first
month of treatment, and then usually at 6 monthly in-
tervals unless prevented by intercurrent illness or subject
availability. Data included baseline demography, cause
of renal failure, comorbidity, residual renal urine vol-
ume and solute clearance, peritoneal solute clearance,
and membrane function using the PET. The reason for
discontinuing PD was also noted and classified, as de-
scribed previously [14].
The PD population was previously censored in 1995
and 1998, at which time survival analyses and descrip-
tions of longitudinal membrane function were described
and published [4, 14]. Between 1990 and 1995 patients
were treated with standard CAPD (4 × 2L), with no at-
tempt to increase dialysis dose in response to lost residual
renal function. Between 1995 and 1998, patients who had
become malnourished on peritoneal dialysis had an in-
crease in delivered peritoneal Kt/V of 25%, resulting in
an achieved increase of 18% [15]. Since 1998, an increas-
ing proportion of patients were treated with APD when
anuric to achieve clearances (target creatinine clear-
ance of 60L/week/1.73m2), as described in the European
Automated Peritoneal Dialysis Outcome Study [3, 16],
and icodextrin was used in patients with solute transport
>0.64 with increasing frequency. The relevance of these
differences in prescription practice is their influence on
peritoneal glucose exposure (see below). With a handful
of exceptions, all patients were treated throughout with
lactate-buffered (40 mmol), pH 5.2, conventional dialysis
solutions.
Demographic and comorbidity data
Comorbidity was documented as described previ-
ously and validated by other prospective studies [17–19].
Briefly, 7 comorbid domains are considered, including
noncutaneous malignancy, ischemic heart disease, pe-
ripheral vascular disease (including cerebro- and ren-
ovascular), left ventricular dysfunction (moderate to
severe hypokinesia on echocardiogram), diabetes mel-
litus, systemic collagen vascular disease, and any other
condition known to reduce life expectancy. The comor-
bid score for each patient is simply the number of these
domains affected, giving a theoretical maximum of 7
(although >5 has not been observed in our patients). The
grade of comorbidity is derived directly from this score.
Grade 0 (low risk) is a zero score, grade 1 (medium risk)
is a score of 1 or 2, and grade 2 (high risk) a cumulative
score of 3 or more.
Measures of solute clearance, membrane function,
blood biochemistry, and glucose exposure
Dialysis dose and residual renal function (RRF), peri-
toneal solute transport, and plasma albumin were mea-
sured at baseline and every 6 months while the patients
remained on PD as described previously [14]. Briefly,
the dialysis dose and RRF was calculated as the weekly
Kt/Vurea from the 24-hour urinary and dialysate clear-
ance by direct measurement of urea in urine and each
dialysate exchange. The volume of distribution for urea
was calculated from the Watson formula. The PET was
used to measure peritoneal solute transport and ultrafil-
tration capacity [13]. Briefly, a standard 4-hour dwell pe-
riod was used (first exchange of the day), using a 2.27%
glucose concentration 2-L volume exchange. The patient
used their usual overnight dialysis regimen, and both
the overnight and test drainage volumes were measured.
The dialysate:plasma ratio of creatinine at the comple-
tion of the 4-hour dwell period (D/Pcreat) was used as
the estimate of low-molecular-weight solute transport.
Using this method, the CV for measurements performed
6 months apart is ∼10% [20]. Net ultrafiltration (UF ca-
pacity) was calculated from the drained volume, weighed
after the flush for the next dialysis exchange was per-
formed. Plasma and dialysate concentrations of urea, cre-
atinine, and glucose were determined on an automated
discrete random access analyzer (DAX 72; Bayer Instru-
ments, Basingstoke, UK). Plasma albumin levels were
measured using the Bromocresol green method. Peri-
toneal glucose exposure was calculated by summing the
number of exchanges performed multiplied by their con-
centration. Thus, a patient using 4 × 2L exchanges of
1.36% glucose would obtain a value of 5.44, whereas
an APD patient using 6 exchanges, 3 of 1.36%, 2 of
2.27%, and one of 3.86% would be 12.28. This approach to
quantifying glucose exposure takes into account both the
amount (exchange number) and the concentration differ-
ences, but not the difference that might be attributed to
exchange length (e.g., 4 overnight exchanges in APD may
not be equivalent to the same 4 exchanges delivered over
24 hours in CAPD). However, the numbers of patients
on APD during the first year of therapy in this study co-
hort were very small (baseline N = 9, at 6 months N =
22, and 12 months N = 18), making this very unlikely to
be a significant confounding factor.
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Table 1. Baseline patient demography
Male Female All patients
Number 317 (55%) 257 (45%) 574
Age in years 58.8 (16.2) 56.6 (15.9) 57.8 (16.1)
Proportion diabetic 19% 20% 20%
Comorbidity score 0.98 (1.1) 0.93 (1.06) 0.96 (1.1)
Comorbidity grade 0.67 (0.69) 0.64 (0.64) 0.66 (0.67)
Plasma albumin g/L 36.4 (5.5) 36.8 (5.4) 36.6 (5.5)
Urine volume mL 1086 (779)a 795 (614) 954 (722)
Weight kg 72.7 (15.2)a 63.6 (15.7) 68.6 (16.1)
Body surface area m2 1.82 (0.28)a 1.64 (0.22) 1.74 (0.27)
Residual Kt/V 1.16 (1.04) 0.99 (1.08) 1.17 (1.02)
Total Kt/V 2.6 (1.02) 3.4 (1.06) 2.9 (1.11)
Solute transport 0.67 (0.12)a 0.63 (0.12) 0.65 (0.13)
(D/Pcreat at 4 hours)
Ultrafiltration capacity mL 418 (273)b 472 (261) 443 (269)
Different between genders, aP < 0.001, bP = 0.034.
Statistical analysis
At baseline, 6, and 12 months data are expressed as
mean values ± SD. After this time period, all patients
had measures of membrane function performed at least
yearly, in many cases, every 6 months, and in some cases
more frequently. If a patient had more than one PET in
a 12-month period, this was averaged on an individual
basis and then the data expressed for the whole popula-
tion on an annual basis. Between group comparisons of
patients was made using unpaired t tests [except when
multiple groups were compared, when a one-way analy-
sis of variance (ANOVA) was used], whereas longitudinal
changes in membrane function were made with paired t
tests. Linear correlations were performed using Pearson’s
test, having first explored the data to check that the rela-
tionship was not better described by a nonlinear function.
When more that one linear correlation was found, then
dominant relationships were explored using multiple re-
gression. Statistical analyses were performed using SPSS,
version 12 (Chicago, IL, USA).
RESULTS
Patient demography and baseline membrane function
The demographic details of the 574 patients included
in this analysis are summarized in Table 1. The numbers
of patients at each time point on PD are shown in the
legend of Figure 1. Primary diagnoses of renal failure
were glomerulonephritis 22.5%, small kidneys/unknown
19%, diabetic nephropathy 15.8%, reflux nephropathy/
interstitial nephritis 8.9%, renovascular disease 7.5%,
hypertensive nephropathy 7%, polycystic renal disease
7%, surgical/obstructive 6.3%, myeloma 2.3%, and other
3.2%. Comparison of baseline membrane function be-
tween these diagnostic categories revealed no significant
differences, with the exception of those with polycystic
kidney disease, in whom solute transport was significantly
lower (mean value 0.577) compared to most groups (over-
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Fig. 1. The upper panel shows the linear best-line fit for the relation-
ship between solute transport and UF capacity at each time-point dur-
ing the study. The gradients (±95% CI), shown in the lower panel are
remarkably similar, but tend to become steeper at 6 and 7 years.
all mean 0.651). These patients had the least comorbid-
ity of any diagnostic group (P = 0.001) and the high-
est body surface area (BSA, P = NS). It can be seen
(Table 1) that men had significantly higher solute trans-
port than women, with an associated reduction in ultrafil-
tration capacity. Men had a larger urine volume, although
when corrected for weight, this was not significant, and
the normalized residual urea clearances were not differ-
ent. At baseline, a number of factors correlated, albeit
weakly, with peritoneal solute transport, including age
(r = 0.15, P = 0.002), grade of comorbidity (r = 0.1, P =
0.038), residual urine volume (r = 0.11, P = 0.018), and
plasma albumin (r = −0.42, P < 0.001), but not weight,
height, BSA, or either total or residual renal urea clear-
ance. On multivariate analysis (see Table 2) only albumin,
gender, and residual urine volume remained significant
independent covariates, accounting for just 21% of the
variability. The only independent covariate to correlate
(inversely) with UF capacity at baseline was the peri-
toneal solute transport.
Cross-sectional relationship of membrane parameters
At each of the time points on treatment (i.e., base-
line, every 6 months, and then yearly over a total of
7 years) there was a consistent inverse correlation be-
tween solute transport and ultrafiltration capacity. The
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Table 2. Multivariate regression of factors associated with baseline
peritoneal solute transport
Standardized
b coefficient t P value
Model constant 17.74 <0.001
Age (transport increases with age) 0.076 1.45 0.15
Grade of comorbidity −0.046 −0.921 0.358
Baseline urine volume (higher 0.148 3.19 0.002
transport associated with
higher urine volume)
Gender (transport increased in men) −0.096 −2.1 0.036
Baseline plasma albumin (higher −0.422 −8.9 <0.001
transport associated with lower
plasma albumin)
ANOVA for model P < 0.001, R2 = 0.215.
Pearson correlation coefficient for this relationship was
–0.401 at baseline and varied between –0.24 and –0.51, but
was always statistically significant, the P value depend-
ing on the number of observations, but ranging between
0.042 and <0.0001. The linear regression lines obtained
at each time point are summarized in Figure 1, where it
can be seen that the gradient remains stable for the first
few years of treatment, but appears steeper after 5 years
(not significant). In each case, fitting of the data with non-
linear functions did not improve the goodness of fit.
Longitudinal relationship of membrane parameters
Solute transport increased significantly in the 6 months
following commencement of peritoneal dialysis, a trend
that continued throughout the course of treatment (see
Fig. 2). Conversely, ultrafiltration capacity declined with
time on treatment, but only after 12 months on therapy.
When the longitudinal relationship between changing so-
lute transport and UF capacity is plotted together (see
Fig. 3), on the background of the relationship between
these parameters determined from cross-sectional anal-
ysis above (as shown in Fig. 1), it can be seen that their
relative change to each other in time is not exactly as
predicted. The early increase in solute transport is not
associated with a fall in UF capacity as anticipated. Later
on, the fall in UF capacity is disproportionately large for a
given rise in solute transport. This would suggest that the
earlier changes in membrane function differ qualitatively
from those occurring later in treatment.
Analysis of early changes in membrane function
Further analysis of factors potentially associated with
the early increase in solute transport was undertaken. In
contrast to baseline, at 12 months there was a weak but
significant correlation between solute transport and BSA
(r = 0.14, P = 0.025). On multiple regression analysis (see
Table 3), this was not an independent covariate if gen-
der was kept in the model. If gender was dropped from
the model, BSA remained a significant positive correlate
(P = 0.009), with very little change in the overall predic-
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Fig. 2. Longitudinal changes in solute transport (A) and UF capacity
(B) for the whole cohort. A significant increase in solute transport was
seen by 6 months and for each subsequent time point, P = 0.008 to <
0.001. A reduction in UF capacity occurred at 24 months and beyond,
P = 0.047 to <0.001. For numbers of patients at each time point, see
legend to Figure 1.
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Fig. 3. The actual mean values (SE bars) for solute transport and UF
capacity at each time point (baseline, 6 months, and then yearly over
7 years, indicated as months) are shown superimposed upon the mean
linear regression line (see Figure 1 for individual lines and numbers
of patients at each time point). There is relative preservation of UF
capacity early during treatment that later reduces disproportionately.
tive power of the model (R2 = 0.11). Another important
difference between the models described in Tables 2 and
3 is that by 12 months, higher solute transport is associ-
ated with a lower urine volume, whereas the inverse was
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Table 3. Multivariate regression of factors associated with peritoneal
solute transport measured at 12 months
Standardized
b coefficient t P value
Model constant 10.5 <0.001
Age (transport increases with age) 0.028 0.4 0.689
Grade of comorbidity 0.057 0.823 0.411
Urine volume at 12 months (higher −0.139 −2.25 0.025
transport associated
with lower urine volume)
Gender (transport higher in men) −0.166 −2.45 0.016
Body surface area 0.091 1.35 0.18
Plasma albumin at 12 months (increased −0.233 −3.7 0.001
transport associated with
lower plasma albumin)
ANOVA for model P < 0.001, R2 = 0.136.
true for baseline solute transport. The weak relationship
of solute transport to grade of comorbidity was present
at 6 and 12 months, reflecting the differences at baseline,
such that solute transport appears to increase in parallel
independent of the comorbid load.
Patients were divided into 2 groups according to
whether they had a significant increase ( D/Pcreat ≥0.1)
or decrease ( D/Pcreat ≥−0.1) in solute transport during
the first year of treatment. Defined in this way, 3 times
as many patients experienced a significant rise in trans-
port (N = 91) compared to those in whom it was re-
duced (N = 30), whereas the relative proportions having
an increase or decrease in transport of <0.1 were almost
identical. In comparing these 2 groups there was no dif-
ference in age, gender split, patient size, prevalence of
diabetes, grade, or score of comorbidity at baseline (see
Table 4). Those experiencing an increase in solute trans-
port had significantly higher plasma albumin and lower
residual urine volume at baseline, and, as would be ex-
pected, had lower transport and higher UF capacity at
the start of treatment and vice versa. Indeed the 2 groups
appear to swap over at 6 months, at which time they have
identical mean solute transport and UF capacities, sug-
gesting that the relationship between these parameters
is not fundamentally different in these 2 patients groups.
The differences in albumin, therefore, are likely to reflect
the phenomenon of regression to mean, as there is a neg-
ative relationship between solute transport and plasma
albumin at each time point due to increased peritoneal
protein clearance. Multiple regression, excluding albu-
min because of this problem with autocorrelation, but
including glucose exposure, indicated that only one fac-
tor, baseline urine volume, was predictive of changes in
solute transport, such that lower volume was associated
with an increase (P = 0.004), although the overall signif-
icance of the model was borderline (ANOVA, P = 0.07)
with an R2 value of 0.038.
Because the relative preservation of ultrafiltration
compared to the changes in solute transport do not ap-
Table 4. Comparison between patients with an early and significant
increase or decrease in solute transport of clinical parameters
measured at baseline, 6, and 12 months
Increase Decrease
in solute in solute
transport transport
N = 91 N = 30
Age years 56.1 ± 16.8 56.6 ± 17.3
Height cm 163.3 ± 19.6 161.1 ± 11.2
Grade of comorbidity 0.64 ± 0.62 0.59 ± 0.73
Residual Kt/Vurea (baseline) 0.97 ± 0.77 1.33 ± 0.97a
Residual Kt/Vurea (6 months) 0.66 ± 0.69 0.83 ± 1.0
Residual Kt/Vurea (12 months) 0.52 ± 0.69 0.75 ± 1.0
Total Kt/Vurea (baseline) 2.82 ± 0.9 3.10 ± 1.0
Total Kt/Vurea (6 months) 2.52 ± 0.84 2.75 ± 0.93
Total Kt/Vurea (12 months) 2.32 ± 0.91 2.72 ± 1.1
Solute transport (baseline) 0.54 ± 0.09 0.77 ± 0.08f
Solute transport (6 months) 0.65 ± 0.1 0.68 ± 0.1
Solute transport (12 months) 0.71 ± 0.1 0.62 ± 0.09f
UF capacity (baseline) mL 532 ± 209 267 ± 307f
UF capacity (6 months) mL 411 ± 196 404 ± 237
UF capacity (12 months) mL 394 ± 241 463 ± 230
Plasma albumin (baseline) g/L 38.5 ± 5.0 35.7 ± 5.5b
Plasma albumin (6 months) g/L 36.6 ± 4.6 36.7 ± 4.4
Plasma albumin (12 months) g/L 36.0 ± 5.1 36.8 ± 4.6
Urine volume (baseline) mL 761 ± 512 1134 ± 828c
Urine volume (6 months) mL 626 ± 562 786 ± 781
Urine volume (12 months) mL 540 ± 624 571 ± 794
Average glucose exposure (baseline) 6.51 ± 1.97 7.68 ± 3.2d
Average glucose exposure (6 months) 7.78 ± 2.6 6.98 ± 1.7
Average glucose exposure (12 months) 8.12 ± 2.7 7.09 ± 2.06e
Between group unpaired t test: aP = 0.059; bP < 0.02; cP = 0.004; dP = 0.067;
eP = 0.079; fP < 0.001.
pear to be related to the early changes in membrane
function, the possibility that it was due to informative
censoring was considered. If patients with relatively poor
UF capacity for a given solute transport are more likely
to leave PD due to either death or transfer, then this
could result in an apparent improvement in UF capacity;
14.5% of patients left PD during the first 12 months of
treatment due either to death or technical failure. Com-
pared to those remaining on PD, baseline UF capacity
was identical (443.2 vs. 442.7 mL), despite slightly higher
solute transport characteristics on the early failure group
(0.688 vs. 0.64, P = 0.01), commensurate with the appar-
ent link with age and comorbidity. If anything, therefore,
those patients leaving the dialysis program due to death
or technique failure during the first year of treatment had
relatively higher UF capacity than would be expected for
their solute transport, indicating that preservation of UF
capacity at 12 months was not simply a function of infor-
mative censoring.
Analysis of late changes in membrane function
The disproportionate fall in UF capacity seen later
in the course of PD, in particular, beyond 4 years, was
more exaggerated in patients who developed ultrafiltra-
tion failure. Of the 192 observed technical failures in PD,
48 (25%) had ultrafiltration failure as the primary rea-
son for switching to hemodialysis. It can be seen from
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Fig. 4. Longitudinal changes in solute transport (A) and UF capacity
(B) for the patients who subsequently developed UF failure () and the
remainder of the cohort (). Despite better membrane function at the
start of treatment, the rate of increase in solute transport tends to be
faster with significantly worse UF capacity at 24 and 48 months, P <
0.05.
Figure 4 that these individuals had relatively good mem-
brane function, in particular, UF capacity, on commenc-
ing PD compared to their peers, indicating this was an
acquired problem with membrane function in the major-
ity of cases. They experienced a similar or more acceler-
ated rise in solute transport with time on treatment, and
a disproportionately large fall in UF capacity.
For the whole population, these later changes in mem-
brane function were analyzed according to the average
use of glucose during the first year of dialysis therapy. In
patients using an average daily cumulative glucose con-
centration load of 6% or less (which reflects typically
a regimen that uses the lowest glucose concentrations
throughout the day), membrane function was almost un-
changed for the first 4 years of treatment. In contrast,
those using higher glucose concentrations had a much
more rapid increase in solute transport that was associ-
ated with a disproportionate fall in the UF capacity (see
Fig. 5). At baseline, these patients had higher solute trans-
port (0.66 vs. 0.63, P = 0.025) and worse UF capacity
(421 vs. 471 mL, P = 0.054), were older (59.9 vs. 53.2,
P < 0.001), had more comorbid conditions (1.1 vs. 0.67,
P < 0.001) and, most important of all, less residual urine
volume (832 vs. 1138 mL, P < 0.001) that persisted over
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Fig. 5. In this case two lines are plotted, that for patients with low
() and high () intraperitoneal glucose exposure during the first 12
months of dialysis treatment. At each time point, the latter group has
higher solute transport and less UF capacity, but in those exposed to
low glucose concentrations, membrane function is stable for the first
4 years of therapy, and UF capacity never becomes disproportionately
low. See Figure 3 for description of this graph format.
the next 5 years (typically, half the urine volume at each
time point).
DISCUSSION
The purpose of this analysis was to provide a compre-
hensive description of longitudinal changes in 2 easily
measured aspects of membrane function, solute transport
and ultrafiltration capacity, concentrating in particular on
their changing relationship with time. The previous ob-
servations that solute transport tends to increase, and UF
capacity decrease, with time on therapy were endorsed
[21–23]. However, the relatively large numbers of pa-
tients in the study and the prolonged period of follow-
up enabled demonstration that the relationship between
these 2 parameters changes qualitatively with time on
treatment. Early increases in solute transport are not as-
sociated with the expected fall in UF capacity, whereas
later on, this becomes disproportionate, especially in
those individuals with clinical evidence of ultrafiltration
failure, or the early use of hypertonic glucose associated
with loss of residual renal function.
Baseline membrane function
There is a large degree of variability on peritoneal
membrane function at the start of treatment between pa-
tients, and yet, it is difficult to see what accounts for this.
Despite the inclusion of a number of clinical variables in
both univariate and multivariate analysis, only ∼20% of
the variability in solute transport can be accounted for,
and for most variables this is negligible (e.g., age accounts
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for about 2%). Some of this might be due to the lack of
precision in measuring solute transport, although this is
quite reproducible with a coefficient of variation less than
10%. This cannot be said for UF capacity, where the CV is
closer to 50% of the net UF volume. This may well explain
the lack of correlation between any of the clinical factors,
with the exception of the well-described relationship with
solute transport. However, it must also be remembered
that UF capacity is a measurement that lumps together
many aspects of membrane function, including fluid re-
absorption by lymphatics and other pathways combined
with osmotic conductance of the membrane across both
inter- and transcellular pores, none of which are measured
in this study.
The finding that solute transport tends to be higher in
older patients with more comorbidity is similar to obser-
vations made in other population studies [5, 17, 24]. Few
studies have included multivariate analysis of this issue,
however, and it would appear that when other factors
are included, namely, gender, urine volume, and plasma
albumin, that they disappear, although age remains im-
portant in one large study of Australasian patients [25].
It could be argued that albumin should not be included
in this model as it is not a true baseline value, but rather a
consequence of starting dialysis, resulting from increased
albumin clearance in those with high solute transport.
Whether this is included or not, however, the other factors
(gender and residual urine volume at baseline) remained
significant. The relationship with urine volume was un-
expected, and may reflect a tendency to commence PD
earlier in patients with worse comorbidity. This may re-
sult in a better correlation in the multivariate model than
with grade of comorbidity due to the more continuous
nature of this covariate. It has, however, been suggested
that solute transport is increased due to uremia at base-
line, per se, linked perhaps by inflammation [26]. Unfor-
tunately, this study did not include an independent mea-
sure of inflammation, such as C-reactive protein (CRP)
or interleukin-6 (IL-6).
The observation that men tend to have higher so-
lute transport, independent of age and comorbidity, is
best explained by their relatively larger size compared to
women. Interestingly, if the initial solute transport is cor-
rected for BSA, then this gender difference completely
disappears (0.445 ± 0.83 D/Pcreatinine ratio/m2 in men vs.
0.445±0.82 in women). In Australasians, men also tended
to have higher transport, although no analysis of BSA was
made in this study [25]. Both the 3-pore and distributed
models of membrane function predict that the rate of
solute transport would be increased when a larger mem-
brane surface area is in contact with dialysate, albeit that
it is the effective vascular area rather than the anatomic
membrane area that is important. In this context, the
observation that the patients with polycystic kidneys
have the lowest solute transport but highest mean BSA
(1.83 m2) illustrates the complexity of these associations.
They had less comorbidity, which partly explains the low
transport, but it may also be that there is relatively less
peritoneal contact area with dialysate due to distortion
of the peritoneal cavity by the presence of their enlarged
kidneys.
Early changes in membrane function
As reported previously, there was an early increase in
peritoneal solute transport during the first year of treat-
ment that was already apparent by 6 months [21]. This
has not been a universal finding [27], however, and some
authors have suggested that the early changes in mem-
brane function reflect a regression to the mean, rather
than a clear trend [28]. This study, through its relatively
large numbers, indicates that both phenomena are in fact
occurring. As indicated above, the reproducibility of this
measure means that a change in the D/P creatinine ratio
of less than 0.1 cannot be considered as significant. This
was confirmed in the present analysis, as patients experi-
encing a change in ratio of less than 0.1 were equally likely
to go in either direction. When the analysis was confined
to patients with a larger change (>0.1), then this was 3
times more likely to be an increase. There is, therefore,
considerable noise in the data, but a clear tendency to
increase transport that will not be apparent in studies of
smaller patient numbers.
It is of considerable interest that this early rise in solute
transport is not associated with a fall in UF capacity. This
is not due to lack of study power, as the expected relation-
ship appears after 12 months when patient numbers are
smaller. Likewise, it does not appear to be due to informa-
tive censoring. The possibility that it was due to inherent
differences in membrane function in those patients whose
membranes changed significantly during the first year of
therapy, in either direction, also seems unlikely because
both of these groups experienced appropriate changes in
UF capacity for their given alteration in transport sta-
tus. Rather, it seems to have been a general phenomenon
across the whole patient cohort. The finding of a stronger
relationship, albeit still a weak one, between transport
and body surface area at 12 months, dominated in the
multiple regression by gender (a major determinant of
BSA), raises the possibility that the area relationship be-
tween solute transport and peritoneal contact has become
more apparent. It is possible to envisage that an early in-
crease in contact area might result in an increase in ultra-
filtration. While a large surface area will increase the rate
of loss of the osmotic gradient, it could at the same time
increase the ultrafiltration coefficient of the membrane,
which is determined by the liquid permeability (Lp)
area (S) product, LpS. If Lp was unaffected in the early
stages of PD, then an increase in S could result in an in-
crease in LpS that counterbalanced the effect of increased
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glucose absorption, giving an overall preservation of
osmotic conductance, as has been demonstrated in com-
puter models of membrane function [29].
Late changes in membrane function
In contrast to these early changes, but by the same to-
ken, it would appear that later on in the treatment the
converse it true (i.e., that there is a relative reduction
in osmotic conductance that is disproportionate to the
changes in solute transport). This was more exaggerated
in patients who subsequently went on to develop clini-
cal ultrafiltration failure, in keeping with cross-sectional
studies that have indicated that in addition to high so-
lute transport there is at least one other cause of poor
UF capacity [11]. The precise mechanism is unclear, but
appears to affect free water transport disproportionately,
either by reducing membrane Lp, or by influencing the
reflection coefficient for glucose, especially across aqua-
porins. The current longitudinal study establishes that this
is clearly an acquired problem, as these patients had nor-
mal, or even better, membrane function at the start of
treatment. It is interesting to speculate what these func-
tional changes mean in the context of the recently docu-
mented long-term morphologic changes to the peritoneal
membrane. In particular, the changes of membrane thick-
ening and vascular sclerosis observed in the Peritoneal
Biopsy Registry might be responsible for the dispropor-
tionate fall in UF capacity [30].
CONCLUSION
The main risk factors associated with this change in
membrane function were already identifiable within the
first year of treatment. Increased early exposure of the
membrane to glucose was associated with a faster in-
crease in solute transport, even allowing for the higher
value at baseline, and almost exclusively with the late
disproportionate fall in UF capacity. This is in keeping
with previous observations of solute transport [31], in-
cluding a selected group of long-term PD patients from
this cohort published previously [32]. As in this previous
report, it is not possible to dissect out the different risk
factors for changing membrane function from each other
as they coexist. It can be said, however, that in patients
who start life on PD with less efficient membranes, who
are also older with more comorbidity and, perhaps most
importantly, lose their residual renal function early, thus
necessitating greater use of hypertonic exchanges, there
is a significantly greater risk of developing longitudinal
detrimental changes in membrane function. Peritonitis
could be added to this list of risk factors, not analyzed
in the current study due to its considerable complexity,
but previously shown in a subgroup of these patients [21]
and in other studies to be a contributory factor [33–35].
This study effectively predates the use of the newer, bio-
compatible dialysis solutions. It does, however, provide
further evidence for their need in hopefully preventing
membrane damage, or at least delaying it, in the future.
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